Free Trial
→ Amazon coin set to soar 25X – starting December 16th? (From True Market Insiders) (Ad)

Y-mAbs Therapeutics Q1 2023 Earnings Report

Y-mAbs Therapeutics logo
$10.57 -1.22 (-10.35%)
(As of 12/3/2024 ET)

Y-mAbs Therapeutics EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.16
One Year Ago EPS
-$0.64

Y-mAbs Therapeutics Revenue Results

Actual Revenue
$20.30 million
Expected Revenue
$15.55 million
Beat/Miss
Beat by +$4.75 million
YoY Revenue Growth
+93.30%

Y-mAbs Therapeutics Announcement Details

Quarter
Q1 2023
Date
5/8/2023
Time
After Market Closes

Conference Call Resources

Powered by Quartr
One coin could soar when Trump’s elected … (Ad)

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Click here to find out more about what could be Trump and JD Vance’s favorite coin.

Y-mAbs Therapeutics Earnings Headlines

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
November 27, 2024 | markets.businessinsider.com
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference
November 27, 2024 | globenewswire.com
Lock in this disruptor’s share price before 12/5
Spencer Rascoff co-founded Zillow. Austin Allison sold his company to Zillow for $125M. Now they’ve joined forces to launch a venture transforming the $1.3T vacation home market – and the results are already turning heads. This company is leading the co-ownership revolution, offering buyers a chance to own a fraction of a luxury vacation home instead of the entire thing. It’s a model that’s unlocked new demand and earned them over $100M in gross profits in four years.
December 4, 2024 | Pacaso (Ad)
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.38 Average PT from Analysts
November 24, 2024 | americanbankingnews.com
Y-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement
November 22, 2024 | benzinga.com
Oppenheimer Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Outperform Recommendation
November 19, 2024 | msn.com
See More Y-mAbs Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Y-mAbs Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Y-mAbs Therapeutics and other key companies, straight to your email.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

View Y-mAbs Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles